1 / 26

An Overview of European Commission Activities on Infectious Diseases

An Overview of European Commission Activities on Infectious Diseases. Ole Olesen Unit Infectious Diseases and Public Health Directorate-General for Research and Innovation European Commission. STOA – Aviesan Workshop, Bruxelles – 19 June 2012.

drake-olsen
Download Presentation

An Overview of European Commission Activities on Infectious Diseases

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. An Overview of European Commission Activities on Infectious Diseases Ole Olesen Unit Infectious Diseases and Public Health Directorate-General for Research and Innovation European Commission STOA – Aviesan Workshop, Bruxelles – 19 June 2012

  2. The role of the European Commission - Research and innovation Develop and implement the European research and innovation policy agreed by the European Parliament and European Council. Funds research through multi-annual framework programmes for research (since 1984). 7th Framework Programme (2007-2013) has a total budget of 53 billion € - 4% of the total EU budget. The European Commission manages about 5% of total public spending in R&D in the European Union.

  3. The 7th EU Framework Programme (2007-2013) Total funding: € 53 billion

  4. The power of collaboration EU27

  5. Improving health of European citizens Main policy drivers: Increasing competitiveness of European health-related industries Global health issues, incl. emerging epidemics

  6. Objectives for Infectious Diseases in FP7:to improve prevention, diagnostics and treatment of infectious diseases by supporting scientific collaboration between • Countries • Sectors – public and private • Area of research Approximate annual average budget for infectious diseases in FP7: €100 million

  7. Key priorities for infectious diseases in the Health Theme • Emerging infectious diseases • Influenza and other emerging diseases (incl vector-borne diseases) • Anti-microbial resistance • Poverty-related diseases • HIV/AIDS, Tuberculosis, malaria • Neglected Infectious diseases

  8. Distribution in FP7 – so far Neglected infectious diseases Projects: 15 EU contribution: € 65 M Antimicrobial resistance Projects: 26 EU contribution: € 131 M Emerging infectious diseases (incl. influenza) Projects: 29 EU contribution: € 141 M HIV/AIDS, malaria, tuberculosis Projects: 51 EU contribution: € 206 M

  9. FP7-funded projectson antimicrobial resistance “EU Research on Antimicrobial Resistance” presents a selection of these projects: • Bacterial infections: 20 projects • Viral infections: 7 projects • Protozoan infections: 4 projects • Fungal infections: 1 project 26 projects in the Health Theme: €131 Mio http://ec.europa.eu/research/health>>Infectious Diseases >>Anti-Microbial Drug Resistance

  10. Co-operation between EU Member States: Joint programming on AMR • Pulls together national research efforts, uses public resources better, and tackles key common challenges • Initiative lead by Sweden • 18 Countries BE, CH, CZ, DE, DK, ES, FI, FR, GR, IL, IT, NL, NO, PL, RO, SE,TK and UK involved • Only 2 countries (DE and NL) have earmarked programmes for AMR research funding – the others fund AMR research as a result of bottom-up competition. • Development of a common vision and strategic research agenda – expected this year • Implementation of joint activities in 2013?

  11. Emerging infectious diseases (including influenza) 29 projects with total EC funding of €141M 16 projects exclusively on human influenza €49M 3 projects on influenza and other emerging pathogens €36M 10 projects on emerging diseases excluding influenza €56M

  12. HIV / AIDS • Key goals in HIV/AIDS research: 18 projects, €84million • Basic science 3 projects, €1.5M • Drug discovery 3 projects, €8.5M • Vaccines 5 projects, €32.0M • Microbicides 1 projects, €12.5M • Diagnostics 2 projects, €2.0M • Clinical management/treatment 4 projects, €24.0M • Overarching ERA-NET 1 project, €2.0M WHO (2008) The Global Burden of Disease: 2004 Update, World Health Organisation, Geneva UNAIDS World AIDS day report, 2011

  13. Tuberculosis • Key goals in tuberculosis research: 15 projects, €66 million • Basic science/host-pathogen interaction 7 projects, €14.5M • Drug discovery 3 projects, €21.0M • Vaccines 2 projects, €12.5M • Diagnostics 2 projects, €6.0M • Clinical management/public health 1 project, €12.0M WHO (2008) The Global Burden of Disease: 2004 Update, World Health Organisation, Geneva.

  14. Malaria • Key goals in malaria research: 18 projects, €56million • Basic science/host-pathogen interaction 4 projects, €20.3M • Vector research 5 projects, €20.8M • Drug discovery 3 projects, €4.6M • Vaccines 5 projects, €7.4M • Diagnostics 1 project, €2.8M WHO (2008) The Global Burden of Disease: 2004 Update, World Health Organisation, Geneva.

  15. Neglected infectious diseases • Key goals in NID research: 15 projects, €65M • Protozoa (Leishmaniasis, Sleeping sickness, Chagas) • Bacteria (Buruli Ulcer, Diarrhoeal diseases) • Helminths (Schistosomiasis, Onchocerciasis, Filariasis) • Basic immunology 5 projects, €13.1M • Vector control/public health 7 projects, €10.5M • Drug discovery 6 projects, €11.0M • Vaccines 7 projects, €25.7M • Diagnostics 3 projects, €4.7M WHO (2008) The Global Burden of Disease: 2004 Update, World Health Organisation, Geneva. Hotez et al. (2009) Lancet 373:1570-1575.

  16. Collaborative projects improves the European Research Infrastructure • Consist of 23 beneficiaries from 16 countries + more than 100 collaborating centres • Access to data from over 250,000 HIV positive people • Coordinator: Prof. Kholoud Porter, MRC clinical trials unit, London, UK • EU contribution: € 12 M • Unique resource 16 16

  17. European Developing Countries Clinical Trials Partnership (EDCTP) • Public-Public Partnership: Joint initiative between 16 Member States and European Commission, established under art. 185 • Independent legal entity (EEIG) • Coordination of European national programmes for clinical trials in Africa for HIV/AIDS, malaria, TB • EC contribution of 200 mill Euro + MS contribution of 200 mill Euro • Launched in 2004, to be renewed 2014 (EDCTP-2) 200 M € 200 M € 17 17

  18. Innovative Medicines Initiative (IMI) • Public-private partnership, initiative under Article 187 • Collaboration between EC and the European Federation of Pharmaceutical Industries and Associations (EFPIA) as a Joint Technology Initiative under FP7 • Objective: to make drug discovery and development more efficient; to bring better medicines faster to patients; and to attract research investment to Europe • Support / Funding of research activities following open Calls and independent review 18 18

  19. Next steps… • FP7 • Next call for proposals under Health (to be published in July 2012) contains new opportunities for building research infrastructures • Large Topics (EU contribution up to 24 M Euro) on "Clinical management of patients in severe epidemics" • Medium-sized topic (EU contribution up to 6 M Euro) on "Drug discovery platform for neglected parasitic diseases"

  20. The EU Framework Programme for Research and Innovation 2014-2020 THE Future Horizon 2020 Research and Innovation

  21. Three priorities: Excellent science (≈ 30%) Industrial leadership (≈ 30%) Societal challenges (≈ 40%) • Commission has proposed €80 billion budget for 2014-2020 • Legislative decision by MS and EP during 2012-2013 • Horizon 2020 will start 1 January 2014

  22. Among the Societal Challenges identified : HEALTH, DEMOGRAPHIC CHANGE AND WELL-BEING • How to provide better health, while • maintaining an economically sustainable healthcare system ? • More health for the money !

  23. HEALTH, DEMOGRAPHIC CHANGE AND WELL-BEINGMain Specific Research Lines Considered • Effective health promotion and disease prevention • Understanding the determinants of health, improving health promotion and disease prevention • Developing effective screening programmes and improving the assessment of disease susceptibility • Improving surveillance and preparedness of infectious diseases • Developing better preventive vaccines and evidence-based vaccination schemes

  24. HEALTH, DEMOGRAPHIC CHANGE AND WELL-BEINGMain Specific Research Lines Considered • Manage, treat and cure diseases and disabilities • Understanding disease • Improving diagnosis • Using in-silico medicine for improving disease management and prediction • Treating disease • Transferring knowledge to clinical practice • Individual empowerments for self-management of health and integrated care

  25. HEALTH, DEMOGRAPHIC CHANGE AND WELL-BEINGMain Specific Research Lines Considered • Translating research into better healthcare • Better use of health data • Improving scientific tools and methods to support policy making and regulatory needs • Active ageing, independent and assisted living • Optimising the efficiency and effectiveness of healthcare systems and reducing inequalities

  26. Thank you European Commission DG Research and Innovation Infectious Diseases and Public Health

More Related